United States

A snapshot of PrEP scale-up, registration and resources for the United States.

  • 266,000-271,000
    Estimated Number of Current PrEP Users

    Aggregates numbers reported from demonstration projects, PEPFAR dashboard and program/country reports where available. This is presented as a range due to difficulty in tracking precise numbers and possible double reporting.

Data Updated: December 31, 2018

Drug Registration Status

  • Gilead's Truvada (TDF/FTC) registration
    Approved
  • Generic versions of TDF/FTC for prevention
    Not submitted

Types of Delivery Projects

  • Clinical trials
  • Demonstration projects — which road-test the use of new options in real-world settings—not in a trial site. They have a formal evaluation component that is designed to address specific elements of introduction such as infrastructure needs and ways individuals can integrate it into daily activities
  • Large-scale implementation initiative — funded/implementer involvement and investment in some or all steps related to comprehensive introduction that may or may not use government clinics as the primary service delivery point – e.g., Kenya’s Jilinde program
  • National level — PrEP availability in government clinics

Research, Demonstration and Implementation Projects

Policy Framework

Funding

  • NICHD
  • California HIV/AIDS Research Program
  • California Collaborative Treatment Group
  • CDC Foundation
  • NIAAA
  • Public Health Foundation Enterprises, Inc.
  • UCLA

Eligibility Criteria

Recommended indications for PrEP use by MSM

  • Adult man
  • Without acute or established HIV infection
  • Any male sex partners in past 6 months
  • Not in a monogamous partnership with a recently tested, HIV-negative man AND at least one of the following: any anal sex without condoms (receptive or insertive) in past 6 months, any STI diagnosed or reported in past 6 months, is in an ongoing sexual relationship with an HIV-positive male partner

Recommended indications for PrEP use by heterosexually active men and women

  • Adult person
  • Without acute or established HIV infection
  • Any sex with opposite sex partners in past 6 months
  • Not in a monogamous partnership with a recently tested HIV-negative partner AND at least one of the following: is a man who has sex with both women and men (behaviorally bisexual); infrequently uses condoms during sex with 1 or more partners of unknown HIV, status who are known to be at substantial risk of HIV infection; is in an ongoing sexual relationship with an HIV-positive partner

Recommended indications for PrEP use by injection drug users

  • Adult person
  • Without acute or established HIV infection
  • Any injection of drugs not prescribed by a clinician in past 6 months AND at least one of the following: any sharing of injection or drug preparation equipment in past 6 months; been in a methadone, buprenorphine or suboxone treatment program in past 6 months; risk of sexual acquisition

Resources for United States